文献速递淋巴瘤

靶向CERS6-AS1/FGFR1轴作为合成致死脆弱性以抑制套细胞淋巴瘤中基质细胞支持的增殖

Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma.
PubMed 文献 · Leukemia · 2024-07-13

本研究在套细胞淋巴瘤(MCL)中鉴定出长链非编码RNA CERS6-AS1在基质微环境中表达升高并与不良总生存相关。机制上CERS6-AS1通过核仁素调控FGFR1转录稳定性,且与癌症干细胞特征及Wnt信号正相关。联合核仁素靶向药物与FGFR1抑制可逆转干细胞特征并抑制原代MCL细胞在基质层上的生长。

要点

  • CERS6-AS1在MCL中上调,与不良总生存相关,在基质微环境中原代MCL表达升高。
  • 黏附于基质层的MCL亚群比悬浮对应细胞表现出更强的癌症干细胞特征。
  • 联合核仁素靶向药物与FGFR1抑制可逆转癌症干细胞特征并抑制原代MCL细胞在基质层上的生长。

核心结论

  • CERS6-AS1、核仁素和FGFR1轴参与肿瘤细胞与基质细胞相互作用的调控网络,靶向该非编码RNA在MCL中具有治疗潜力。

研究设计与样本

  • 研究为实验性研究,鉴定MCL中上调的长链非编码RNA CERS6-AS1并探索其机制与治疗策略。

主要发现

  • CERS6-AS1在MCL中上调并与不良总生存相关,在基质微环境中原代MCL及黏附于基质层的部分MCL细胞中表达升高。
  • 黏附于基质层的MCL亚群比悬浮对应细胞表现出癌症干细胞特征。
  • 下调CERS6-AS1降低FGFR1表达,归因于其与RNA结合蛋白核仁素的相互作用丧失。
  • 计算机模拟方法发现核仁素与FGFR1的5'UTR直接相互作用,从而调控FGFR1转录本稳定性。
  • CERS6-AS1与癌症干细胞特征及Wnt信号呈正相关。

关键数值与推荐

  • 联合核仁素靶向药物与FGFR1抑制显著逆转癌症干细胞特征并消除原代MCL细胞在基质层上的生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The interaction between stromal and tumor cells in tumor microenvironment is a crucial factor in Mantle cell lymphoma (MCL) progression and therapy resistance. We have identified a long non-coding RNA, CERS6-AS1, upregulated in MCL and associated with poor overall survival. CERS6-AS1 expression was elevated in primary MCL within stromal microenvironment and in a subset of MCL cells adhered to stromal layer. These stromal-adhered MCL-subsets exhibited cancer stem cell signatures than suspension counterparts. Mechanistically, we found that downregulating CERS6-AS1 in MCL reduced Fibroblast Growth Factor Receptor-1 (FGFR1), expression attributed to loss of its interaction with RNA-binding protein nucleolin. In addition, using in-silico approach, we have discovered a direct interaction between nucleolin and 5'UTR of FGFR1, thereby regulating FGFR1 transcript stability. We discovered a positive association of CERS6-AS1 with cancer stem cell signatures, and Wnt signaling. Building on these, we explored potential therapeutic strategies where combining nucleolin-targeting agent with FGFR1 inhibition significantly contributed to reversing cancer stem cell signatures and abrogated primary MCL cell growth on stromal layer. These findings provide mechanistic insights into regulatory network involving CERS6-AS1, nucleolin, and FGFR1 axis-associated crosstalk between tumor cells and stromal cell interaction and highlights therapeutic potential of targeting a non-coding RNA in MCL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jindal U, Mamgain M, Nath UK, et al. Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma. Leukemia. 2024. PMID: 39003397. doi:10.1038/s41375-024-02344-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。